HLA-mismatched allogeneic hematopoietic stem cell transplantation for standard-risk advanced hematological disease using low-dose alemtuzumab

HLA-mismatched allogeneic hematopoietic stem cell transplantation for standard-risk advanced hematological disease using low-dose alemtuzumab - HLA-mismatched HSCT for standard-risk hematological disease using low-dose alemtuzumab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018283

Enrollment

Registered

2015-07-13

Start date

2015-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Standard-risk advanced hematological disease(leukemia and malignant lymphoma in remission, MDS, IMF, and SAA)

Interventions

Conditioning regimen: Patients who are intolerable to conventional conditioning regimen due to either higher age (55&gt

=), previous ASCT, organ dysfunction, or active infection will receive regimen 2-1 or 2-2.(Mainly, regimen 2-1 will be selected in patients with lymphoid malignancy and regimen 2-2 will be selected in

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who do not have an available HLA-matched or one locus-mismatched related donor. 2.Patients who have a two- or three-locus-mismatched haploidentical related donor in good condition. 3.Patients who do not have an HLA-matched or one allele-mismatched unrelated donor, or patients whose disease status preclude time-consuming donor coordination. 4.Patients with standard-risk advanced hematological disease. High-risk acute leukemia, advanced CML, refractory malignant lymphoma, advanced MDS, acute or lymphoma type ATLL, advanced IPF or refractory severe aplastic anemia are regarded as advanced hematological disease, and in advanced disease, leukemia and malignant lymphoma in remission, MDS, IPF or severe aplastic anemia are included in stndard-risk group. 5.Patients who are 16 to 70 years old 6.Patients in performance status of 0 or 1. 7.Patients whose major organ functions are preserved.

Exclusion criteria

Exclusion criteria: 1.Patients with poorly controlled active infection. 2.Patients with coexistence of malignancy. 3.Patients who are pregnant or nursing. 4.Patients with serious mental disorder. 5.Patients with HIV antibody positive. 6.Patients who are allergic to drugs used in conditioning regimen or GVHD prophylaxis.

Design outcomes

Primary

Measure	Time frame
Disease-free survival at 1 year	—

Countries

Japan

Contacts

Public ContactShinichi Kako

Saitama Medical Center, Jichi Medical University Division of Hematology

shinichikako@asahi-net.email.ne.jp0486472111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026